Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30831846 | 1.00 | ESR1 (0.35) | ESR1ESR2S1PR1TTRKDM4E | |
| SCHEMBL7379965 | 0.82 | S1PR1 (0.45) | ESR1ESR2S1PR1TTRKDM4E | |
| SCHEMBL19154351 | 0.81 | ESR1 (0.54) | ESR1ESR2S1PR1KDM4ECYP3A4 | |
| SCHEMBL21346932 | 0.81 | PTGS1 (0.41) | ESR1ESR2S1PR1PTGS1PTGS2 | |
| SCHEMBL8065786 | 0.79 | TRPA1 (0.43) | ESR1ESR2S1PR1KDM4EPTGS1 | |
| SCHEMBL29377856 | 0.78 | ALDH1A1 (0.40) | ESR1ESR2TTRKDM4ECYP3A4 | |
| SCHEMBL540384 | 0.78 | ALDH1A1 (0.40) | ESR1ESR2TTRKDM4ECYP3A4 | |
| SCHEMBL24219430 | 0.77 | HRH3 (0.39) | ESR1ESR2SKP2 | |
| SCHEMBL171208 | 0.77 | ESR1 (0.40) | ESR1ESR2S1PR1TSHRPTGS1 | |
| SCHEMBL26586432 | 0.77 | ESR1 (0.35) | ESR1ESR2S1PR1PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110536885-B | Process for producing difluoromethylene compound | 佐藤制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| EP-3368524-B1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-08-18 | — | — | EP | disclosed |
| US-11084792-B2 | Method for producing difluoromethylene compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2021-08-10 | — | — | US | disclosed |
| US-20200190038-A1 | METHOD FOR PRODUCING DIFLUOROMETHYLENE COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-18 | — | — | US | disclosed |
| US-10640486-B2 | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-05-05 | — | — | US | disclosed |
| EP-3617197-A1 | METHOD FOR PRODUCING DIFLUOROMETHYLENE COMPOUND | Sato Pharmaceutical Co., Ltd. (JP) | 2020-03-04 | — | — | EP | disclosed |
| US-20180319771-A1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190038-A1 | METHOD FOR PRODUCING DIFLUOROMETHYLENE COMPOUND | HACL2, MGLL, ABL1 | ESR1 4213/4885ESR2 4414/4885S1PR1 2630/4885 |
| US-10640486-B2 | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | ESR1 3007/4885ESR2 2542/4885S1PR1 462/4885 |
| US-11084792-B2 | Method for producing difluoromethylene compound | HACL2, MGLL, ABL1 | ESR1 4213/4885ESR2 4414/4885S1PR1 2630/4885 |
| US-20180319771-A1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, BDKRB1, BDKRB2 | ESR1 3007/4885ESR2 2542/4885S1PR1 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.